Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 27, 2026, 5:11 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 335 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Drug Allergy Clear all
Terminated Phase 1Phase 2 Interventional Results available

Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis

NCT02037347
View directory record Official record
Conditions
Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
Interventions
Palifermin
Drug
Lead sponsor
Brett King
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Bridgeport, Connecticut • New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 30, 2016 · Synced Oct 27, 2026, 5:11 AM EDT
Withdrawn Not applicable Interventional

Assessment of a Mobile Intervention to Increase Adherence to Asthma Medication Among Adolescents

NCT02426814
View directory record Official record
Conditions
Asthma
Interventions
Inhaler sensor, Mobile application for asthma adherence
Device · Behavioral
Lead sponsor
CoheroHealth
Industry
Eligibility
11 Years to 19 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2023
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

The Study is Enrolling Kids From 8 to 17 Years Old. The BreathSmart Device Attaches to the Inhaler to Measure Adherence.

NCT03734861
View directory record Official record
Conditions
Asthma
Interventions
BreatheSmart System, Standard of Care
Device · Other
Lead sponsor
Connecticut Children's Medical Center
Other
Eligibility
8 Years to 17 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated Apr 7, 2023 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

NCT03056599
View directory record Official record
Conditions
Soft Tissue Sarcoma Adult
Interventions
Multiple drug microinjection, CIVO device
Drug · Device
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
3
States / cities
Lake Success, New York • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 24, 2021 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Medication Adherence With Telehealthcare Medication Therapy Management

NCT03978936
View directory record Official record
Conditions
Uncontrolled Asthma, Young Adults
Interventions
Medication Therapy Management (MTM) Video Telehealthcare, Electronic Adherence Self-Management (EAM)
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 35 Years
Enrollment
375 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
21
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 12 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 3 Interventional

Study to Find Out Whether Participants With a History of Stuffy Nose Due to Allergic Reactions in the Nose Would Intend to Buy Drug Phenylephrine Hydrochloride Extended Release Tablets After Receiving it Once in This Study

NCT04534452
View directory record Official record
Conditions
Nasal Congestion Due to Allergic Rhinitis
Interventions
Phenylephrine HCl (Sinus Comfort, BAY112476)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 60 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Blue Bell, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Drug-Drug Interaction Study of Telotristat Etiprate and Fexofenadine in Healthy Subjects

NCT02157558
View directory record Official record
Conditions
Drug Interactions
Interventions
Fexofenadine, Telotristat etiprate
Drug
Lead sponsor
Lexicon Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2014
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Sep 8, 2014 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 1 Interventional

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents

NCT01831505
View directory record Official record
Conditions
Lymphoma
Interventions
Multiple drug microinjection: rituximab, vincristine, doxorubicin, bendamustine, prednisolone or a combination of them
Drug
Lead sponsor
Presage Biosciences
Industry
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Feb 27, 2017 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Results available

Testing Effectiveness of Losartan in Patients With EoE With or Without a CTD

NCT01808196
View directory record Official record
Conditions
Eosinophilic Esophagitis, Connective Tissue Disorders
Interventions
Losartan Potassium
Drug
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
5 Years to 21 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Mason, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 24, 2020 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

Olaparib Treatment in Relapsed Germline Breast Cancer Susceptibility Gene (BRCA) Mutated Ovarian Cancer Patients Who Have Progressed at Least 6 Months After Last Platinum Treatment and Have Received at Least 2 Prior Platinum Treatments

NCT02282020
View directory record Official record
Conditions
Relapsed Ovarian Cancer, BRCA Mutation, Platinum Sensitivity
Interventions
OLAPARIB, Single agent chemotherapy
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 130 Years · Female only
Enrollment
266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
22
States / cities
Birmingham, Alabama • Mobile, Alabama • Sacramento, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jul 26, 2022 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 2 Interventional

Parent-Youth Teamwork in Pediatric Asthma Management

NCT00166582
View directory record Official record
Conditions
Asthma
Interventions
electronic medication monitoring system, parent-adolescent communication and problem-solving skills
Device · Behavioral
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
9 Years to 15 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
2
States / cities
Kansas City, Missouri • Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Jul 2, 2007 · Synced Oct 27, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional

Depsipeptide (Romidepsin) in Treating Patients With Recurrent Ovarian Epithelial or Peritoneal Cavity Cancer

NCT00091195
View directory record Official record
Conditions
Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
Interventions
romidepsin
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older · Female only
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
2
States / cities
High Point, North Carolina • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2013 · Synced Oct 27, 2026, 5:11 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Sampling for Research Related to Sickle Cell Disease

NCT00542230
View directory record Official record
Conditions
Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 26, 2026 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Asthma Link: A Real World Application of School Supervised Asthma Therapy

NCT04942379
View directory record Official record
Conditions
Childhood Asthma
Interventions
Asthma Link, Enhanced Usual Care
Other
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
6 Years to 17 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 19, 2024 · Synced Oct 27, 2026, 5:11 AM EDT
Completed No phase listed Observational

Asthma and Osteopathic Manipulative Treatment

NCT03864354
View directory record Official record
Conditions
Asthma
Interventions
Osteopathic Manipulative Treatment
Procedure
Lead sponsor
Des Moines University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
Des Moines, Iowa
Source: ClinicalTrials.gov public record
Updated Mar 6, 2019 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

NCT01872819
View directory record Official record
Conditions
Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Chronic Myelomonocytic Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts
Interventions
antitumor drug screening assay, chemotherapy, biological therapy
Other · Drug · Biological
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 27, 2026, 5:11 AM EDT
Not listed Not applicable Interventional

Detroit Young Adult Asthma Project

NCT03121157
View directory record Official record
Conditions
Asthma
Interventions
Multi-Component Technology Based Intervention
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 29 Years
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated May 9, 2022 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

An Open Label, Safety Study to Assess the Potential for Adrenal Suppression.

NCT02932891
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
DSXS topical
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
6 Months to 17 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated Dec 7, 2018 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Not applicable Interventional Results available

Immune Dysfunction in Allergic Asthma

NCT00189228
View directory record Official record
Conditions
Asthma
Interventions
Xolair
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
18 Years to 45 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 27, 2026, 5:11 AM EDT
Completed Phase 3 Interventional Results available

A Study of Lanadelumab in Teenagers and Adults to Prevent Acute Attacks of Non-histaminergic Angioedema With Normal C1-Inhibitor (C1-INH)

NCT04206605
View directory record Official record
Conditions
Angioedema
Interventions
Placebo, Lanadelumab
Other · Drug
Lead sponsor
Takeda
Industry
Eligibility
12 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
20
States / cities
Birmingham, Alabama • Scottsdale, Arizona • San Diego, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 27, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

Improving Medication Adherence Using Family-focused and Literacy-sensitive Strategies

NCT05548413
View directory record Official record
Conditions
Medication Adherence, Heart Failure
Interventions
FamLit, Attention Control
Behavioral
Lead sponsor
Jia-Rong Wu
Other
Eligibility
18 Years and older
Enrollment
328 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 27, 2026, 5:11 AM EDT
Recruiting Not applicable Interventional

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

NCT04199026
View directory record Official record
Conditions
Metastatic Sarcoma, Recurrent Sarcoma, Resectable Sarcoma
Interventions
Doxorubicin, Doxorubicin Hydrochloride, Drug Delivery Microdevice, Everolimus, Ganitumab, Ifosfamide, Irinotecan, Pazopanib, Polyethylene Glycol, Temozolomide, Temsirolimus, Therapeutic Conventional Surgery, Vincristine
Drug · Device · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
10 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 27, 2026, 5:11 AM EDT
Not yet recruiting Not applicable Interventional

Asthma Ctrl SMART Trial

NCT07512622
View directory record Official record
Conditions
Asthma in Children, Asthma Chronic
Interventions
Asthma Ctrl+, Control
Behavioral
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
12 Years to 18 Years
Enrollment
389 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Aurora, Colorado • Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 27, 2026, 5:11 AM EDT
Terminated Phase 2 Interventional

Comparing Asthma Action Plans for Pediatric Asthma

NCT00136305
View directory record Official record
Conditions
Asthma
Interventions
Pictorial asthma action plan, Written asthma action plan
Behavioral
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
6 Years to 18 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Aug 26, 2021 · Synced Oct 27, 2026, 5:11 AM EDT